IRD
Opus Genetics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.18
−1.89%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$5.27
From 52W high−14.66%
Volume5.47M
Market cap$430.95M
P/E (TTM)—
P/S (TTM)43.7x
Div yield—
Key dataSep 18, 2026
Open
$5.27
From 52W high
−14.66%
Volume
5.47M
Market cap
$430.95M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.6x
P/E (TTM)
—
RSI (14)
57.1
MomentumView details →
1D Return
−1.89%
YTD Return
+154.98%
SummaryUpdated Jun 1, 2026
Opus Genetics, Inc. (NASDAQ:IRD) is a clinical-stage ophthalmic biopharmaceutical company founded in 2018 and headquartered in Farmington Hills, Michigan. Originally known as Ocuphire Pharma, Inc., the company went public in 2015 and focuses on developing innovative therapies for patients with refractive and retinal eye disorders. The company operates in the specialized field of ophthalmology, targeting unmet medical needs in eye care through both commercially available products and an active clinical development pipeline.
Similar companies
Latest newsMore news →
Opus Genetics reported positive three- and six-month results from the low-dose first cohort of its Phase 1/2 BIRD-1 trial of OPGx-BEST1, showing vision improvements.11d agoOpus Genetics, Inc. reported its Q2 2026 financial results, with revenue of $0.8 million, a net loss of $8.1 million, and diluted EPS of -$0.14, compared to a net loss of $7.4 million in Q2 2025.46d ago